Breaks Categories: Stock Spotlights

TuesdaySep 07, 2021 2:34 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level. A recent article reads, “Mr. McKee cited the benefits that come with the use of psilocybin in treating pain. For one, he discussed their effectiveness without the accompanying risk of addiction associated with opioids. He also…

Continue Reading

ThursdaySep 02, 2021 12:37 pm

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Expanded Vision for Neurology Telemedicine Combines Diagnostic Solutions, AI, ML, and Cloud-Based Infrastructure

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cost-effective and portable proprietary brain diagnostic solutions — the NeuroCap(TM) and NeuroEEG(TM) — that are positioned to disrupt the electroencephalogram (“EEG”) market. With nearly every U.S. state experiencing a neurologist shortfall and experts warning that access to high-level care and diagnosis is immediately required to reduce mental disability, improve patient outcomes and increase the wellbeing of the current pool of neurologists, Brain Scientific aims to support the industry through its diagnostic solutions. A recent article explains: “These portable devices are part of the company’s…

Continue Reading

TuesdayAug 31, 2021 12:13 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Leveraging Strategic Board Appointment to Execute Visionary Strategy

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently announced its appointment of Jerry White as an advisor to the company. White has been recognized for his efforts in engaging large audiences to power global movements and is a recognized leader of the International Campaign to Ban Landmines and a co-recipient of the 1997 Nobel Peace Prize. Given his expertise, ambition and successful track record, White is an excellent addition to the company’s advisory board as it focusses on achieving strategic goals while working towards its overall vision. “Never shying away…

Continue Reading

FridayAug 27, 2021 10:44 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Modernizing, Increasing Accessibility to Brain Diagnostics

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with its FDA-cleared NeuroCap(TM) and NeuroEEG(TM), which are already patented in the United States, China and Europe. As the company’s first commercialized devices, they are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. A recent article reads, “Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices.…

Continue Reading

TuesdayAug 24, 2021 1:20 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Identifying Significant Trends in Plant Therapy

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with researchers to provide a full turnkey solution for clinical studies from start to finish. “As research restrictions throughout the U.S. lift, RYAH Group is standing by, ready to provide IoT hardware, software and data analytics that reduce variations in patient-related clinical trials. One of the areas that the U.S. is poised to explore is cannabis in sports medicine,” reads a recent article. Sports organizations must rethink their strict policies with the legalization of recreational and medicinal cannabis across the country. The good news is…

Continue Reading

FridayAug 20, 2021 12:56 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Tapping into AI, ML Technology to Facilitate Early Diagnosis of Brain Disorders

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, commenced its three-stage development process with the first phase in 2018 that resulted in the creation of the NeuroCap(TM) and NeuroEEG(TM). “The second phase, currently ongoing, is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency and accuracy of diagnostic analytics provided by the application,” reads a…

Continue Reading

ThursdayAug 19, 2021 12:53 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Collaborate to Build Leading Rare Cannabinoid Company

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids. The company is creating a pipeline of drug candidates to treat various diseases with high unmet medical needs. “In a move to grow its market presence and strengthen its operations, the company announced that it had entered into a non-binding letter of intent (“LOI”) to acquire BayMedica Inc.,” reads a recent article. “This announcement followed the two parties’ reciprocal research collaboration agreement back in November 2020, which saw them collaborate on several projects since. The agreement allowed BayMedica to assess…

Continue Reading

TuesdayAug 17, 2021 2:51 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a clinical trial for eating disorders including binge eating and hypothalamic obesity. “With the growing popularity and proliferation of psychedelics, many companies are pursuing therapeutic indications with the compounds,” reads a recent article discussing Tryp’s positioning. “However, very few have initiated phase 2a studies. Tryp Therapeutics…

Continue Reading

FridayAug 13, 2021 2:30 pm

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) State-of-the-Art IoT Products Provide Holistic View for Optimal Research

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is standing by to provide a wealth of smart devices, artificial intelligence and an integrated platform that will fully support the U.S. as it explores the benefits, risks and effects of cannabis. “U.S. researchers can benefit from RYAH Group’s state-of-the-art IoT suite of products. The technology collects, analyzes and leverages objective data throughout the research process. As a result, the company boasts one of the largest plant-based medicine databases globally with 200,000 plus registered users. The company’s ecosystem of products allows data to be collected from seed…

Continue Reading

ThursdayAug 12, 2021 12:51 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Groundbreaking Tech to Push Boundaries in Neurology Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This comes as the brain-computer interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. It is a promising approach to overcoming paralysis by decoding brain signals…

Continue Reading